1RT Stock Chart & Stats
€0.02
<€0.01(58.33%)
At close: 4:00 PM EST
€0.02
<€0.01(58.33%)
Day’s Range― - ―
52-Week Range€0.02 - €0.02
Previous CloseN/A
Volume90.00K
Average Volume (3M)90.00K
Market Cap
€4.44M
Enterprise Value€2.97M
Total Cash (Recent Filing)€930.28K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.33
Next Earnings
Feb 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,609,750,000
10 Day Avg. Volume90,000
30 Day Avg. Volume90,000
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-6.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetThe absence of debt limits interest and refinancing burdens, preserving flexibility while Nuformix develops its pipeline. Although the asset base is small, low leverage means future financing or partnering decisions are not immediately constrained by existing borrowings.
2025 Loss ReductionThe substantial reduction in annual net loss indicates improved cost control or the absence of prior one-off effects. If maintained, lower losses could extend the company’s operating runway and reduce the amount of capital required before potential development or partnering proceeds.
Focused Inhaled Drug PipelineThe strategy combines known drugs with proprietary lung-delivery formulations intended to improve local treatment and reduce systemic side effects. This focused approach may support differentiated development opportunities across respiratory and fibrotic indications while limiting reliance on entirely novel drug discovery.
Bears Say
No Recent RevenueThe absence of reported revenue over three recent years shows that Nuformix has not yet established meaningful commercial traction. Without product sales or recurring income, progress depends on advancing candidates toward partnering or commercialization rather than funding operations through an operating revenue base.
Persistent Structural LossesNuformix remains structurally loss-making despite the smaller 2025 deficit, so its pipeline currently consumes resources rather than generating earnings. Continued losses can constrain investment in development and leave future progress dependent on further financing, licensing proceeds, or other non-operating funding.
Negative Cash GenerationPersistent negative operating and free cash flow indicates that the business cannot currently fund its activities from internally generated cash. The renewed cash burn in 2025, together with ongoing losses, increases dependence on external funding and makes the timing of future financing strategically important.
Nuformix Plc News
1RT FAQ
What was Nuformix Plc’s price range in the past 12 months?
Nuformix Plc lowest stock price was €0.02 and its highest was €0.02 in the past 12 months.
What is Nuformix Plc’s market cap?
Nuformix Plc’s market cap is €4.44M.
When is Nuformix Plc’s upcoming earnings report date?
Nuformix Plc’s upcoming earnings report date is Feb 03, 2027 which is in 124 days.
How were Nuformix Plc’s earnings last quarter?
Nuformix Plc released its earnings results on May 28, 2026. The company reported €0 earnings per share for the quarter.
Is Nuformix Plc overvalued?
According to Wall Street analysts Nuformix Plc’s price is currently Overvalued.
Does Nuformix Plc pay dividends?
Nuformix Plc does not currently pay dividends.
What is Nuformix Plc’s EPS estimate?
Nuformix Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuformix Plc have?
Nuformix Plc has 2,609,750,000 shares outstanding.
What happened to Nuformix Plc’s price movement after its last earnings report?
Nuformix Plc reported an EPS of €0 in its last earnings report. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Nuformix Plc?
Currently, no hedge funds are holding shares in DE:1RT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuformix Plc
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Evgen Pharma
―
Futura Medical
―
ImmuPharma
―
OptiBiotix Health
―
HemoGenyx Pharmaceuticals Plc
―